Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation

JHOP - April 2022 Vol 12, No 2 - FDA Oncology Update
NEW INDICATIONS
Download PDF

On March 11, 2022, the FDA accelerated the approval of the oral PARP inhibitor olaparib (Lynparza; AstraZeneca) for the adjuvant treatment of adults with HER2-negative, high-risk early breast cancer and deleterious or suspected deleterious germline BRCA mutation after neoadjuvant or adjuvant chemotherapy. Patients must be selected for olaparib therapy for this indication based on an FDA-approved test.

This approval was based on the OlympiA study, a randomized (1:1), double-blind, placebo-controlled, international clinical trial of 1836 patients with HER2-negative, high-risk early breast cancer and germline BRCA mutation who completed definitive local treatment and neoadjuvant or adjuvant chemotherapy. Patients were randomized to 1 year of olaparib 300 mg orally twice daily or to placebo. Patients had to have completed ≥6 cycles of neoadjuvant or adjuvant chemotherapy containing anthracyclines, taxanes, or both. Patients with hormone receptor–positive breast cancer were allowed to continue concurrent treatment with endocrine therapy.

The primary efficacy end point was invasive disease-free survival (IDFS), defined as the time from randomization to the date of first recurrence (ie, invasive locoregional or distant recurrence), contralateral invasive breast cancer, new cancer, or death from any cause.

At a prespecified interim analysis at a median follow-up of 2.5 years, the 3 years IDFS rate was 85.9% in the olaparib arm versus 77.1% in the placebo arm, amounting to 8.8% difference (95% confidence interval [CI], 4.5-13.0) and a hazard ratio (HR) of 0.58 for invasive disease or death (99.5% CI, 0.41-0.82; P <.0001). A total of 56 deaths were reported in the olaparib arm and 86 in the placebo arm, but the difference was not statistically significant (HR, 0.68; 99% CI, 0.44-1.05; P = .02).

The most common (≥10%) adverse reactions in this study were nausea, fatigue (including asthenia), anemia, vomiting, headache, diarrhea, leukopenia, neutropenia, decreased appetite, dysgeusia, dizziness, and stomatitis.

Related Items
Pluvicto FDA Approved for PSMA-Positive Metastatic Prostate Cancer
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Keytruda Monotherapy FDA Approved for Endometrial Carcinoma with a Biomarker
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Kimmtrak, a Bispecific CD3 T-Cell Engager, First FDA-Approved Drug for Unresectable or Metastatic Uveal Melanoma
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in FDA Oncology Update
Orencia First Drug FDA Approved for the Prevention of Acute Graft-versus-Host Disease
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in FDA Oncology Update
Keytruda Now Approved for the Adjuvant Treatment of Stage IIB/IIC Melanoma
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in FDA Oncology Update
Rituximab plus Chemotherapy FDA Approved for Several Pediatric Hematologic Malignancies
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in FDA Oncology Update
FDA Grants Gedatolisib, a Dual PI3K and mTOR Inhibitor, Fast-Track Review for ER-Positive, HER2-Negative Breast Cancer
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in FDA Oncology Update
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.